MAP plus maintenance pegylated interferon alpha-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization

Author(s):
Bielack, S.S.; Smeland, S.; Whelan, J.; Marina, N.; Hook, J.; Jovic, G.; Krailo, M.D.; Butterfass-Bahloul, T.; Kuhne, T.; Eriksson, M.; Teot, L.A.; Gelderblom, H.; Kager, L.; Hall, K.S.; Gorlick, R.G.; Randall, R.L.; Hogendoorn, P.C.W. (0000-0002-1513-8104); Calaminus, G.; Sydes, M.R.; Bernstein, M.L.
Published
2013
Publication type
Article / Letter to editor
Date issued
2013-06-20
Language
English
Is part of
Journal of Clinical Oncology (2013), No. 18
hdl
1887/104678